Human Leukocyte Antigens (HLA)-DR-DQ Disease Association Typing Low Resolution, Blood
Use
Determining class II human leukocyte antigens (HLA) to identify potential disease associations or markers for drug hypersensitivity. This test is useful in determining potential genetic predispositions to certain autoimmune diseases and can be instrumental in identifying patients at risk for drug hypersensitivity reactions.
Special Instructions
If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen. Send whole blood in the original tube and do not aliquot. Specimen acceptability is based on extracted DNA concentration, not sample age.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration and was developed in compliance with CLIA regulations. While it provides valuable insights into genetic predispositions and disease associations, interpretation depends on the specific rationale for ordering the test. The results may need to be integrated with clinical information for a comprehensive understanding.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
LOINC Codes
- 96640-8
- 96625-9
- 57298-2
- 96664-8
- 96673-9
- 53938-7
- 78017-1
- 96654-9
- 96648-1
- 96643-2
Result Turnaround Time
7-17 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
6 mL
Minimum Volume
3 mL
Container
Yellow top (ACD solution A or B)
Collection Instructions
Send whole blood in original tube. Do not aliquot.
Causes for Rejection
Extracted DNA: Reject